| Trial | Regimen | N | Progression-free survival (months) | Median overall survival (months) | Overall response rate | Complete response rate | Toxicity Grade 3-4 | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | Thrombocytopenia | Anaemia | Leucopenia | Toxic deaths | |||||||
| Kaufman 2000 | Gemcitabine, paclitaxel | 6 | NR | 1/6 (17%) | 1/6 (17%) | Not reported separately for 2nd line patients | |||||
| Sternberg 2001 | Gemcitabine, paclitaxel | 15 | 8 | 4/15 (27%) | 13/41 (32%) | 0/41 | 0/41 | 1 | |||
| Kanai 2008 | Gemcitabine, paclitaxel | 20 | 11.5 | 6/20 (30%) | 1/20 (5%) | 6/20 (30%) | 1/20 (5%) | 3/20 (15%) | 0 | ||
| Suyama 2009 | Gemcitabine, paclitaxel | 33 | 11.3 | 10/30 (33%) | 1/30 (3%) | 15/33 (45%) | 2/33 (6%) | 2/33 (6%) | 0 | ||
| Ikeda 2011 | Gemcitabine, paclitaxel | 24 | 6.1 | 12.4 | 10/24 (42%) | 2/24 (8%) | 16/24 (67%) | 7/24 (29%) | 0 | ||
| Takahashi 2006 | Gemcitabine, paclitaxel | 14 | 12.1 (all ps) | 2/14 (14%) | 0/14 | Not reported separately for 2nd line patients | |||||
| Fechner 2006 | Short-term Gem, paclitaxel | 30 | 11 | 13 | 7/14 (50%) | 7/14 (50%) | 0/14 (0%) | 3/14 (21%) | 5/14 (36%) | ||
| Prolonged Gem, paclitaxel | 6 | 9 | 5/13 (39%) | 1/13 (8%) | 2/13 (15%) | 3/13 (23%) | 3/13 (23%) | ||||
| Albers 2011 | Short-term Gem, paclitaxel | 48 | 4.0 | 7.8 | 15/40 (38%) | 5/40 (13%) | 3/40 (8%) | 0 | |||
| Prolonged Gem, paclitaxel | 48 | 3.1 | 8.0 | 17/41 (42%) | 6/41 (15%) | 11/41 (27%) | 2 | ||||
| Kuono 2007 | Carboplatin, paclitaxel | 31 | 3.7 | 7.9 | 10/31 (32%) | 2/31 (6%) | 18/31 (58%) | 0/31 | 11/31 (35%) | 1 (PS 3) | |
| Vaishampayan 2005 | Carboplatin, paclitaxel | 44 | 4 | 6 | 7/44 (16%) | 1/44 (2%) | 23/44 (52%) | 4/44 (9%) | 7/44 (16%) | 16/44 (36%) | 0 |
| Soga 2007 | Carboplatin, paclitaxel | 18 | 4 | 11 | 6/18 (33%) | 0/18 | 9/18 (50%) | 3/18 (22%) | 5/18 (28%) | ||
| Halim 2013 | Methotrexate, paclitaxel, epirubicin, carboplatin | 38 | 12 | 12.5 | 15/38 (39.5%) | 1/38 (3%) | 12 (30%) | 1 (2.5%) | 2 (5%) | ||
| Han 2008 | MVAC | 30 | 5.3 | 10.9 | 9/30 (30%) | 2/30 (7%) | 19/30 (63%) | 9/30 (30%) | 5/30 (17%) | 0 | |
| Gondo 2011 | Gemcitabine, Cisplatin | 33 | 10.5 | 13/33 (39%) | 2/33 (6%) | 22/33 (67%) | 10/33 (30%) | 14/33 (42%) | 15/33 (45%) | 0 | |
| Tu 1995 | Paclitaxel, methotrexate, cisplatin | 25 | NR | 10/25 (40%) | 0/25 | 9/25 (36%) | 8/25 (32%) | ||||
| Uhm 2007 | Paclitaxel, cisplatin | 28 | 6.2 | 10.3 | 10/28 (36%) | 3/28 (11%) | 5/110 (5%) cycles | 1/110 (1%) | 1/110 (1%) | ||
| Bellmunt 2002 | Methotrexate, paclitaxel | 20 | 5 | 6/20 (30%) | 3/20 (15%) | 0/20 | 1/20 (5%) | 0 | |||
| Sweeny 1999 | Paclitaxel, ifosfamide | 13 | 8 | 2/13 (15%) | 2/13 (15%) | 4/13 (34%) | 2/13 (15%) | 1/13 (8%) | |||
| Krege 2001 | Docetaxel, ifosphamide | 22 | 4 | 5/20 (25%) | 4/20 (20%) | 1/53 (2%) | 0/20 | 11/53 (21%) | |||
| Srinivas 2009 | Docetaxel, oxaliplatin | 11 | 7 | 1/11 (9%) | 0/11 | 0 | |||||
| Pagliaro 2002 | Cisplatin, gemcitabine, ifosfamide | 51 | 9.5 | 20/49 (41%) | 2/49 (4%) | 48/51 (94%) had a dose limiting hematologic toxicity | 1 | ||||
| Lin 2007 | Gemcitabine, ifosfamide | 23 | 3.5 | 4.8 | 5/23 (22%) | 1/23 (4%) | 8/23 (35%) | 5/23 (22%) | 10/23 (43%) | ||
| Pectasides 2001 | Gemcitabine, ifosfamide | 34 | 4 | 9 | 7/34 (21%) | 1/34 (3%) | 9/34 (27%) | 4/34 (12%) | 6/34 (18%) | 0 | |
| Dreicer 2003 | Gemcitabine, Docetaxel | 29 | 7.7 | 5/27 (17%) | 1/27 (4%) | 4/29 (14%) | 8/29 (28%) | ||||
| Tsuruta 2011 | Gemcitabine, Carboplatin, Docetaxel | 26 | 5.0 | 12.6 | 9/16 (56%) | 1/16 (6%) | 28/35 (80%) | 18/35 (51%) | 15/35 (43%) | 0 | |
From: 5, Managing locally advanced or metastatic bladder cancer
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.